CTLA4 and neoplasm: Other immunological markers, such as CTLA-4 (an immunomodulatory mediator that downregulates T-cell activation, leading to the suppression of the anti-tumor BCG response), were also evaluated, and decreased levels of serum CTLA-4 were associated with a good response to treatment.